Kruti Patel

Dr. Kruti Patel

University of Tennessee Health Science Center Memphis
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LHLeonard Harris
Leonard Harris
KPKruti Patel
Kruti Patel
MMMichael Martin
Michael Martin
The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy. Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide (LEN) in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.

Verified
Journal Article
Open access
PDF file
MSMatthew K. Stein
Matthew K. Stein
OOOluchukwu Oluoha
Oluchukwu Oluoha
KPKruti Patel
Kruti Patel
AVAri Vanderwalde
Ari Vanderwalde
Precision medicine is essential for the modern care of a patient with cancer. Comprehensive molecular profiling of the tumor itself is necessary to determine the presence or absence of certain targetable abnormalities or biomarkers. In particular, lung cancer is a disease for which targetable genomic alterations will soon guide therapy in the majority of cases. In this comprehensive review of solid tumor-based biomarkers, we describe the genomic alterations for which targeted agents have been approved by the United States Food and Drug Administration (FDA). While focusing on alterations leading to approvals in a tumor-agnostic fashion (MSI-h, TMB-h, NTRK) and on those alterations with approvals in multiple malignancies (BRAF, ERBB2, RET, BRCA, PD-L1), we also describe several biomarkers or indications that are likely to lead to an approved drug in the near future (e.g., KRAS G12C, PD-L1 amplification, HER2 overexpression in colon cancer, HER2 mutations in lung cancer). Finally, we detail the current landscape of additional actionable alterations (EGFR, ALK, ROS1, MET) in lung cancer, a biomarker-rich malignancy that has greatly benefitted from the precision oncology revolution.

29 November 2023 in European Journal of Haematology
Verified
Journal Article
Closed access
UOUgochi Ogu
Ugochi Ogu
AMAyesha Mukhopadhyay
Ayesha Mukhopadhyay
KPKruti Patel
Kruti Patel
MNMarquita N. Nelson
Marquita N. Nelson
KSKayLee S. Strahan
KayLee S. Strahan
KAKenneth I. Ataga
Kenneth I. Ataga

29 September 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
LHLeonard Harris
Leonard Harris
KPKruti Patel
Kruti Patel
MMMichael Martin
Michael Martin
The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy.1 Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.

20 March 2021 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
Mary NguyenMary Nguyen
Mary Nguyen
AUAnna-Carson Rimer Uhelski
Anna-Carson Rimer Uhelski
KPKruti Patel
Kruti Patel
BWBradford Waters
Bradford Waters
AWAlva Weir
Alva Weir
"CLO21-023: Antiviral Therapy Improves Hepatocellular Cancer Survival" published on 17 Mar 2021 by National Comprehensive Cancer Network.